ESTRO 2022 - Abstract Book

S1152

Abstract book

ESTRO 2022

Conclusion Postoperative VBT alone is sufficient for intermediate-risk endometrial cancer. PRT could be recommended for low ACCI patients with LVSI.

Poster (digital): Biomarkers

PO-1358 Neutrophil-To-Lymphocyte Ratio Predicts Recurrence And Response In Stereotactic Brain Radiotherapy

F.C. Di Guglielmo 1 , M. Trignani 2 , M. Lucarelli 3 , L. Caravatta 3 , A. Porreca 4 , M. Di Nicola 5 , D. Genovesi 6

1 SS. Annunziata Hospital,G. D’Annunzio University, Radiation Oncology Unit, Chieti, Italy; 2 SS. Annunziata Hospital, G. D’Annunzio University , Radiation Oncology Unit, Chieti, Italy; 3 SS. Annunziata Hospital, G. D’Annunzio University, Radiation Oncology Unit, Chieti, Italy; 4 G. D'Annunzio University of Chieti-Pescara, Department of Economics, Pescara, Italy; 5 G. D'Annunzio University, Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, Chieti, Italy; 6 "SS Annunziata" Hospital, "G. d'Annunzio" University, Radiation Oncology Unit, Chieti, Italy Purpose or Objective Metastatic brain tumors standard of care is constantly evolving along with technological development in radiation therapy (RT) and with the identification of new prognostic and predictive factors. In the last few years, inflammatory blood markers have emerged as predictive and prognostic factors, particularly the neutrophil to lymphocyte ratio (NLR). This reflects the squilibrium between immune surveillance and tumor progression. In this scenario we aimed to assess the predictive role of NLR on early response in-field control, intracranial control and overall survival after fractionated stereotactic radiotherapy (FSRT) for brain metastases. Materials and Methods We retrospectively evaluated 34 patients with initial presentation of metastatic brain disease, treated with FSRT in our center. Laboratoristic parameters were obtained from blood count performed within one week before the start of RT. NLR, Hemoglobin and Platelets count to lymphocyte ratio were examined to establish their prognostic role respect to overall survival, disease progression and treatment response. Treatment response was evaluated with brain MRI at 3 months from the end of FSRT and then on a quarterly basis for the first two years, according to RECIST criteria. We analyzed time-to- event distributions using Kaplan-Meier's method. Kaplan-Meier curves illustrate the probability of progression in response time for patients with NLR ≥ or < MEDIAN. Results With a median follow-up of 14 months (3-58), a single brain metastasis (range 1-3) was treated in 74% of patients. Treatment schedules adopted ranged from 20 Gy (5 Gy/fx) to 27 Gy (9 Gy/fx). The median age was 59 years (41-81): female=20, male=14. A good Karnofsky Performance Status was detected in 88% of our sample. at the time of treatment 59% of patients was not on steroids. The median NLR value was 2.72 (IQR: 1.69 - 4.54). Patients with a NLR ≥ 2,72 showed a probability of